Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in Alcohol Drinking Behavior
NCT02955186Phase 2Completed
- Sponsor
- Yale University
- Start
- May 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Saracatinib Arm with Placebo Arm (2 arms). Primary endpoints: Change in the Number of Drinks Consumed From Baseline to Day 8 and Craving-Baseline Adjusted Total Area Under the Curve During the Drinking Session Using the Yale Craving Scale at 7 days. Started May 2017; status: completed.
02
Drugs
saracatinib
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT02955186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955186.